



**SERES**  
THERAPEUTICS™

## **Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023**

May 5, 2023

*- Company to report initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1 -*

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2023-- [Seres Therapeutics, Inc.](https://www.serestherapeutics.com) (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 9, 2023 at 8:30 a.m. ET to discuss first quarter results and provide a general business update, including initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1.

To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 5098595. To join the live webcast, please visit the "Investors and News" section of the Seres website at [www.serestherapeutics.com](https://www.serestherapeutics.com).

A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.

### **About Seres Therapeutics**

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres' lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of *C. difficile* infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.

For more information, please visit [www.serestherapeutics.com](https://www.serestherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230505005081/en/): <https://www.businesswire.com/news/home/20230505005081/en/>

### **IR and PR Contact**

Carlo Tanzi, Ph.D.

[ctanzi@serestherapeutics.com](mailto:ctanzi@serestherapeutics.com)

Source: Seres Therapeutics, Inc.